Please login to the form below

Not currently logged in
Email:
Password:

Merck Serono and Takeda reconsider matuzumab development

Merck Serono has announced it is considering whether to further develop its humanised monoclonal antibody drug matuzumab for metastatic colorectal cancer patients.

Merck Serono has announced it is considering whether to further develop its humanised monoclonal antibody drug matuzumab for metastatic colorectal cancer patients.

According to the company, a phase II trial investigating matuzumab in combination with irinotecan in patients with metastatic colorectal cancer (mCRC) who had already failed on multiple prior treatments, including irinotecan, has not met its predefined endpoint of activity.

Swtizerland-based Merck Serono is co-developing matuzumab with Japanese company Taked. According to a statement by Merck Serono, both companies share the view that the study results do not meet expectations.

The companies will continue to study the drug in other tumours including non-small cell lung cancer (NSCLC).

29th August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

Women in science
The role of women in science and technology
Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
Maria Dahl
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
China secures a place at the forefront of innovative medicine...
Virtual Research Grants Submission and Approval Program
Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person....

Infographics